Document resource
Cataract surgery in children with uveitis is associated with an increased risk of postoperative inflammation and complications. Intravitreal dexamethasone (Ozurdex) implants are increasingly used perioperatively to optimiseoutcomes and reduce inflammatory burden. This audit aimed to evaluate the efficacy and safety of pre-operative versus intraoperative Ozurdex administration in paediatricuveitis patients undergoing cataract surgery.A retrospective analysis was conducted of 23 eyes from 18 children who received Ozurdex within three months before-or at the time of cataract surgery 2012–2024. Outcome measures included best-corrected visual acuity (BCVA), intraocular pressure (IOP), and the presence of cystoid macular oedema (CMO) assessed pre-operatively and at three months post-operatively.BCVA improved from a mean of 0.82 logMAR pre-operatively to 0.39 logMAR at three months. Seventeen of 23 eyes (74%) showed improvement in visual acuity, while two eyes worsened due to posterior capsular opacification or recurrent CMO. CMO was present pre-operatively in 14 eyes and resolved in 9 by three months. No new cases of CMO developed. Three eyes had pre-existing ocular hypertension; one developed new IOP elevation post-operatively, managed with topical therapy. Two eyes required repeat Ozurdex injections. No cases of permanent vision loss, lens explantation, or enucleation were recorded.Ozurdex can be used safely in paediatric patients to facilitate cataract surgery with good outcomes. Intraoperative administration was associated with outcomes comparable to pre-operative administration and offered the additional benefit of avoiding a second general anaesthetic. This approach appears to be a safe and effective adjunct in paediatric uveitis surgery with meaningful clinical applicability.